文章摘要

奥希替尼治疗晚期肺腺癌1例并文献复习

作者: 1刘 源, 2倪 渐凤, 1刘 丽娜, 1尹 先哲
1 南阳市第二人民医院肿瘤科,河南 南阳 473012
2 南阳市第二人民医院肿瘤过继免疫疗法重点实验室,河南 南阳 473012
通讯: 刘 源 Email: 396464667@qq.com
DOI: 10.3978/j.issn.2095-6959.2020.02.043

摘要

分析1例晚期肺腺癌患者应用第1代表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)(吉非替尼)治疗耐药后的应用奥希替尼治疗的临床疗效及不良反应。患者应用吉非替尼治疗11个月出现耐药,后给予奥希替尼治疗28个月病情进展,期间未出现严重不良反应。奥希替尼治疗第1代EGFR-TKIs耐药后的晚期肺腺癌患者,临床疗效较好,不良反应少。
关键词: 奥希替尼;耐药;晚期肺腺癌

Observation of clinical efficacy of osimertinib in advanced lung adenocarcinoma: A case report and literature review

Authors: 1LIU Yuan, 2NI Jianfeng, 1LIU Lina, 1YIN Xianzhe
1 Department of Oncology, Nanyang Second People’s Hospital, Nanyang Henan 473012, China
2 Key Laboratory of Adoptive Immunotherapy for Cancer, Nanyang Second People’s Hospital, Nanyang Henan 473012, China

CorrespondingAuthor:LIU Yuan Email: 396464667@qq.com

Abstract

We analyzed the clinical efficacy and adverse reactions of a patient with advanced lung adenocarcinoma who received resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (gefitinib) for treatment with osimertinib, and review the relevant literature. The patient developed resistance after 11 months of treatment with first-generation EGFR-TKIs (gefitinib), and then received osimertinib for 28 months. There were no serious adverse reactions in the treatment of osimertinib. Osimertinib is effective in treating patients with advanced lung adenocarcinoma after resistance to first-generation EGFR-TKIs, with good clinical efficacy and fewer adverse reactions.
Keywords: osimertinib; resistance; advanced lung adenocarcinoma